Owlstone’s breath diagnostic to be used in asthma research
Owlstone’s ReCIVA and FAIMS technologies will be used to discover asthma-specific biomarkers.
Owlstone’s ReCIVA and FAIMS technologies will be used to discover asthma-specific biomarkers.
Trial’s next phase will recruit 3,000 patients across 21 international sites.